Mindera

Mindera is a company that develops and commercializes medical technologies for skin analysis at the molecular level. By utilizing proprietary skin biomarker patches, next-generation sequencing (NGS), and machine learning, the technology generates clinically validated data, reducing healthcare system costs and improving patient outcomes. Mindera has developed a proprietary platform that uses skin biomarker patches to extract RNA from the skin in a simple, fast, and painless manner. The extracted RNA then undergoes next-generation sequencing, allowing Mindera scientists to capture a genetic and transcriptomic snapshot of the skin at the exact moment of testing. This rich, patient-specific dataset is subsequently analyzed through machine learning algorithms to address complex data questions, such as predicting appropriate biologic drugs for patients before treatment selection and initiation. At the heart of MiNDERA’s products is a proprietary microneedle device that enables painless, minimally invasive, and targeted extraction of biomarkers from the skin without the need for a skin biopsy. These biomarkers are then eluted and analyzed using molecular techniques, including PCR and next-generation sequencing, to provide a molecular map of the sampled area.